Marshall Wace, LLP Point Biopharma Global Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $466,960 - $679,787	-70,009 Reduced 69.34%	30,958 $206,000
Q2 2023 Aug 14, 2023	SELL	$6.86 - $10.86 $1.2 Million - $1.89 Million	-174,296 Reduced 63.32%	100,967 $914,000
Q1 2023 May 15, 2023	BUY	$6.78 - $8.1 $1.87 Million - $2.23 Million	275,263 New	275,263 $2 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $833,338 - $1.19 Million	115,102 New	115,102 $890,000
Q2 2022 Aug 15, 2022	SELL	$5.6 - $9.5 $213,416 - $362,045	-38,110 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $181,490 - $270,241	33,240 Added 682.55%	38,110 $304,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $23,522 - $47,482	4,870 New	4,870 $27,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.